The global botulinum toxin in urology market is anticipated to grow at a considerable CAGR of 6.4% during the forecast period (2023-2030). Botulinum toxin A (BoNT-A) is a prescription medicine that is injected into muscles and used to treat leakage of urine (incontinence) in adults with overactive bladder due to neurologic disease. Its mechanism of action in treating OAB and urinary urgency incontinence (UUI) involves inducing flaccid paralysis via blockade of the acetylcholine release at the synaptic junction. In addition, BoNT-A inhibits bladder afferent nerve firing and provides anti-inflammatory effects to manage bladder disorders. The availability of various botulinum toxin products such as disport, botox, and others is anticipated to boost the market growth. In February 2023, according to study of MDPI, which aimed to evaluate the efficacy of intravesical BoNT-A injections for the treatment of pediatric OAB. The study performed a retrospective review of all pediatric patients who received intravesical BoNT-A injections between January 2002 and December 2021. All patients underwent a urodynamic study at baseline and three months after BoNT-A administration. A Global Response Assessment (GRA) score of ?2 at three months after BoNT-A injection was defined as successful treatment.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/botulinum-toxin-in-urology-market
Additionally, the increasing geriatric population associated with urinary tract conditions, especially urinary incontinence, is projected to impact the market’s growth. The senior population, particularly those aged 65 and above, is more prone to urinary incontinence problems, requiring botulinum toxin injections to treat these conditions. The article published by A Place for Mom Canada Inc., Senior Population Statistics: A Portrait of Aging Americans stated that there are 54.1 million adults or 16.3% of the US population are seniors (aged 65 or older). The senior population is expected to rise to 22.0% by 2040 and 25.0% by 2060. 69% of senior adults will need long-term care at some point. Moreover, the growing geriatric population is credited to the increasing demand for botulinum toxin injections. Furthermore, rising investment in the R&D program and exclusive partnerships by key market players to explore the therapeutic use of botulinum toxin in urinary tract conditions is building opportunities for expanding its market over the forecast period. For instance, in February 2022, Vensica Therapeutics, a clinical stage biopharmaceutical company, closed a $19 million investment round. Vensica accomplished a strategic collaboration agreement with Merz Therapeutics in 2021 and the Merz Group participated in Vensica’s financing with up to $3 million, bringing the total round to up to $19 million. Merz Therapeutics, a business of the Merz Group, is a leader in the field of neurotoxins. Vensica exclusively licensed Merz’s botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures. Vensica unlocked the potential of neurotoxins in urology by developing minimally invasive solutions using the unique properties of therapeutic ultrasound to deliver botulinum toxin A to the bladder.
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered-
o By Application
o By End-User
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- includes AbbVie Inc., Merz Pharma, Ipsen Pharma, Galderma Laboratories, L.P., and Allergan PLC, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Botulinum Toxin in Urology Market Report Segment
By Application
- Overactive Bladder
- Neurogenic Detrusor Overactivity
By End-user
- Hospitals
- Urology Clinics
A full report of Botulinum Toxin in Urology Market available @ https://www.omrglobal.com/industry-reports/botulinum-toxin-in-urology-market
Global Botulinum Toxin in Urology Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
Company Profiles
- Allergan PLC
- Bio-Med Pvt. Ltd.
- Biovencer Healthcare Pvt. Ltd.
- Daewoong Pharmaceutical Co., Ltd.
- Eisai Co. Ltd.
- Gufic Biosciences Ltd.
- HUGEL, Inc.
- IntechOpen Ltd.
- Kansas City Urology Care, P.A.
- Medytox Inc.
- Revance Therapeutics, Inc.
- Sun Pharmaceutical Industries Ltd.
- UroGen Pharma Ltd.
- Vensica Therapeutics
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
